Bifogade filer
Kurs
+10,62%
Likviditet
1,41 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-16 | 08:30 | Bokslutskommuniké 2025 |
2025-11-03 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-08-29 | - | Kvartalsrapport 2025-Q2 |
2025-05-30 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2025-05-28 | - | Årsstämma |
2025-04-25 | - | Kvartalsrapport 2025-Q1 |
2025-02-14 | - | Bokslutskommuniké 2024 |
2024-11-01 | - | Kvartalsrapport 2024-Q3 |
2024-08-30 | - | Kvartalsrapport 2024-Q2 |
2024-05-31 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2024-05-30 | - | Årsstämma |
2024-04-26 | - | Kvartalsrapport 2024-Q1 |
2024-02-09 | - | Bokslutskommuniké 2023 |
2023-12-21 | - | Extra Bolagsstämma 2024 |
2023-11-17 | - | Kvartalsrapport 2023-Q3 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-05-12 | - | Kvartalsrapport 2023-Q1 |
2023-04-06 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2023-04-05 | - | Årsstämma |
2023-02-03 | - | Bokslutskommuniké 2022 |
2022-11-07 | - | Kvartalsrapport 2022-Q3 |
2022-10-05 | - | Extra Bolagsstämma 2022 |
2022-08-26 | - | Kvartalsrapport 2022-Q2 |
2022-06-15 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2022-06-14 | - | Årsstämma |
2022-04-29 | - | Kvartalsrapport 2022-Q1 |
2022-02-18 | - | Bokslutskommuniké 2021 |
2021-11-29 | - | Kvartalsrapport 2021-Q3 |
2021-09-23 | - | Extra Bolagsstämma 2021 |
2021-08-30 | - | Kvartalsrapport 2021-Q2 |
2021-06-28 | - | Årsstämma |
2021-06-15 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2021-04-29 | - | Kvartalsrapport 2021-Q1 |
2021-02-19 | - | Bokslutskommuniké 2020 |
2020-11-09 | - | Kvartalsrapport 2020-Q3 |
2020-08-17 | - | Kvartalsrapport 2020-Q2 |
2020-06-26 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2020-06-25 | - | Årsstämma |
2020-05-11 | - | Kvartalsrapport 2020-Q1 |
2020-02-20 | - | Bokslutskommuniké 2019 |
2019-05-10 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2019-05-06 | - | Kvartalsrapport 2019-Q1 |
2019-04-10 | - | Årsstämma |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-12-18 | - | Extra Bolagsstämma 2018 |
2018-10-24 | - | Kvartalsrapport 2018-Q3 |
2018-08-29 | - | Kvartalsrapport 2018-Q2 |
2018-05-24 | - | Kvartalsrapport 2018-Q1 |
2018-04-12 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2018-04-11 | - | Årsstämma |
2018-03-22 | - | Bokslutskommuniké 2017 |
2017-08-29 | - | Kvartalsrapport 2017-Q2 |
2017-05-09 | - | Kvartalsrapport 2017-Q1 |
2017-04-26 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2017-04-25 | - | Årsstämma |
2017-02-24 | - | Bokslutskommuniké 2016 |
2016-11-16 | - | Kvartalsrapport 2016-Q3 |
2016-10-19 | - | Extra Bolagsstämma 2016 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
2016-04-20 | - | Kvartalsrapport 2016-Q1 |
2016-02-25 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2016-02-24 | - | Årsstämma |
2016-02-04 | - | Bokslutskommuniké 2015 |
2015-11-13 | - | Kvartalsrapport 2015-Q3 |
2015-09-04 | - | Kvartalsrapport 2015-Q2 |
2015-07-22 | - | Extra Bolagsstämma 2015 |
2015-05-07 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2015-05-06 | - | Årsstämma |
2015-04-17 | - | Kvartalsrapport 2015-Q1 |
2015-02-20 | - | Bokslutskommuniké 2014 |
2014-12-17 | - | Extra Bolagsstämma 2014 |
2014-11-28 | - | Kvartalsrapport 2014-Q3 |
2014-11-14 | - | Kvartalsrapport 2014-Q3 |
2014-08-29 | - | Kvartalsrapport 2014-Q2 |
2014-06-12 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2014-06-11 | - | Årsstämma |
2014-05-16 | - | Kvartalsrapport 2014-Q1 |
2014-02-21 | - | Bokslutskommuniké 2013 |
2013-11-15 | - | Kvartalsrapport 2013-Q3 |
2013-08-28 | - | Kvartalsrapport 2013-Q2 |
2013-06-17 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2013-06-14 | - | Årsstämma |
2013-05-17 | - | Kvartalsrapport 2013-Q1 |
2013-02-22 | - | Bokslutskommuniké 2012 |
2012-11-30 | - | Kvartalsrapport 2012-Q3 |
2012-07-31 | - | Kvartalsrapport 2012-Q2 |
2012-06-20 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2012-06-19 | - | Årsstämma |
2012-04-20 | - | Kvartalsrapport 2012-Q1 |
2012-02-21 | - | Bokslutskommuniké 2011 |
2011-11-04 | - | Kvartalsrapport 2011-Q3 |
2011-08-12 | - | Kvartalsrapport 2011-Q2 |
2011-05-06 | - | Kvartalsrapport 2011-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
iZafe Group AB (publ) today signed an agreement to acquire its exclusive distributor in the Netherlands, Thuisapparatuur Nederland B.V., which has built a rapidly growing Dosell business in Europe’s largest market for medication dispensers.
The transaction strengthens growth, margins and cash flow and is carried out without dilution for shareholders or the need for external financing. Through the acquisition, iZafe estimates that the ARR target of SEK 10 million can already be achieved during Q4 2025, earlier than the original projection of year-end 2025. The deal also increases the likelihood of reaching the ARR targets for coming years at a faster pace.
Since its founding in 2023, Thuisapparatuur has worked exclusively with the distribution of Dosell and has built a strong local presence in the Netherlands. The company will now become a wholly owned subsidiary within the iZafe Group under the new name Dosell B.V., meaning that the distribution of Dosell in the Dutch market will henceforth be handled directly by iZafe, thereby capturing the full revenue from this important market.
Transaction terms
- Purchase Price: EUR 1.55 million, which includes the assumption of the company’s existing loan.
- Payment terms: The Purchase Price will be settled in seven instalments during the period July 31, 2026 – July 31, 2029. The first two instalments will each amount to 20% of the Purchase Price, while the remaining five will be evenly distributed over the subsequent payment dates.
- Security: In the event of non-payment, the debt may, as a last resort, be converted into shares in iZafe Group under agreed terms.
- Closing: Has taken place today in connection with the signing of the agreement.
- Final obligations: Upon completion of all seven instalments, iZafe Group will have no further payment obligations to the seller.
The transaction is not expected to have a negative impact on iZafe’s liquidity, as the Purchase Price is projected to be fully financed through future cash flows from both the existing and the acquired business. The Purchase Price of EUR 1.55 million largely corresponds to the capital invested to date in Thuisapparatuur, which iZafe considers a sound valuation relative to the company’s established growth and strong market position. It should be noted that Thuisapparatuur has a cash position of approximately EUR 250k included in the acquisition. Excluding this cash, the Purchase Price corresponds to approximately EUR 1.30 million.
Dosell contributes to safer medication management, reduced medication errors and frees up time for healthcare staff – needs that are growing rapidly in line with an aging population. The product has documented high customer satisfaction and generates clear efficiency gains.
The Netherlands is Europe’s largest market for pouch-packed medication, with over 600,000 people receiving their medicine in pouches – the same format Dosell is designed for. The country is also the European market that has advanced the furthest in adopting medication dispensers, with around 17,000 active units, and the market where iZafe is currently growing the fastest.
In 2024, Thuisapparatuur’s revenue amounted to approximately SEK 0.75 million. For the period January–September 2025, the company recorded an average monthly growth rate of approximately 16%. As of September 30, 2025, Thuisapparatuur’s total Annual Recurring Revenue (ARR) amounted to approximately SEK 4.2 million. Following the acquisition, 100% of future revenues from the sale of Dosell in the Netherlands will accrue to iZafe Group, strengthening recurring revenues, improving margins and increasing cash flow.
– This is a strategically important step that gives us direct control over our largest and fastest-growing market. The entire Dutch organization has for several years worked exclusively with Dosell and is already deeply integrated into our product, business model and customer base. This makes it a natural next step for both them and us. Together we strengthen our business, improve profitability and lay the foundation for continued growth across Europe. Our core strategy of expanding through strong partnerships across Europe remains firm, but in the Netherlands it is right that we take the lead ourselves, says Anders Segerström, CEO of iZafe Group.
Contacts
Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm
E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group
About iZafe Group AB (publ.)
iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.
The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.
The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.
iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company’s Certified Adviser is DNB Carnegie Investment Bank AB. Further information is available at www.izafegroup.com
This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-09-30 21:15 CEST.